{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:57:37Z","timestamp":1793069857058,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03061-0","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:10:48Z","timestamp":1758903048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Theranostics in nuclear medicine: the era of precision oncology"],"prefix":"10.1007","volume":"42","author":[{"given":"Noopur","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Alaseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohitas","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artiben","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Awad","family":"Alsaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glowi","family":"Alasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhaskumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupendra","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"Pt 1","key":"3061_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.129332","volume":"260","author":"H Yang","year":"2024","unstructured":"Yang H, Zhou H, Fu M, et al. TMEM64 aggravates the malignant phenotype of glioma by activating the Wnt\/\u03b2-catenin signaling pathway. Int J Biol Macromol. 2024;260(Pt 1):129332. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.129332.","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"3061_CR2","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1007\/s12035-023-03911-w","volume":"61","author":"X Wu","year":"2024","unstructured":"Wu X, Fu M, Ge C, et al. m6A-mediated upregulation of lncRNA CHASERR promotes the progression of glioma by modulating the miR-6893-3p\/TRIM14 axis. Mol Neurobiol. 2024;61(8):5418\u201340. https:\/\/doi.org\/10.1007\/s12035-023-03911-w.","journal-title":"Mol Neurobiol"},{"key":"3061_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113993","volume":"157","author":"D Sun","year":"2023","unstructured":"Sun D, Li X, Nie S, Liu J, Wang S. Disorders of cancer metabolism: the therapeutic potential of cannabinoids. Biomed Pharmacother. 2023;157:113993. https:\/\/doi.org\/10.1016\/j.biopha.2022.113993.","journal-title":"Biomed Pharmacother"},{"key":"3061_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113392","volume":"144","author":"DY Sun","year":"2025","unstructured":"Sun DY, Hu YJ, Li X, Peng J, Dai ZJ, Wang S. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. Int Immunopharmacol. 2025;144:113392. https:\/\/doi.org\/10.1016\/j.intimp.2024.113392.","journal-title":"Int Immunopharmacol"},{"key":"3061_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119513","volume":"585","author":"Y Nie","year":"2020","unstructured":"Nie Y, Li D, Peng Y, et al. Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int J Pharm. 2020;585:119513. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119513.","journal-title":"Int J Pharm"},{"key":"3061_CR6","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.2147\/IJN.S466042","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu Y, Song J, et al. Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic\/photothermal\/chemodynamic treatment of cervical cancer. Int J Nanomed. 2024;19:5837\u201358. https:\/\/doi.org\/10.2147\/IJN.S466042.","journal-title":"Int J Nanomed"},{"issue":"12","key":"3061_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410918","volume":"12","author":"J Du","year":"2025","unstructured":"Du J, Meng X, Yang M, et al. NGR-modified CAF-derived exos targeting tumor vasculature to induce ferroptosis and overcome chemoresistance in osteosarcoma. Adv Sci. 2025;12(12):e2410918. https:\/\/doi.org\/10.1002\/advs.202410918.","journal-title":"Adv Sci"},{"key":"3061_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70048","author":"T Wu","year":"2025","unstructured":"Wu T, Zhao Y, Zhang X, et al. Short-chain acyl post-translational modifications in cancers: mechanisms, roles, and therapeutic implications. Cancer Commun (Lond). 2025. https:\/\/doi.org\/10.1002\/cac2.70048.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"3061_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53826-w","volume":"15","author":"C Tang","year":"2024","unstructured":"Tang C, Wang Z, Xie Y, et al. Classification of distinct tendinopathy subtypes for precision therapeutics. Nat Commun. 2024;15(1):9460. https:\/\/doi.org\/10.1038\/s41467-024-53826-w.","journal-title":"Nat Commun"},{"issue":"2","key":"3061_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.preme.2025.100032","volume":"2","author":"D Li","year":"2025","unstructured":"Li D, Liu Y, Yang Z, Li N, Zhu H. Recent advances of nuclear medicine for tumor precision medicine. Precis Med Eng. 2025;2(2):100032. https:\/\/doi.org\/10.1016\/j.preme.2025.100032.","journal-title":"Precis Med Eng"},{"issue":"17","key":"3061_CR11","doi-asserted-by":"publisher","first-page":"21546","DOI":"10.1021\/acsami.4c00793","volume":"16","author":"Y Chen","year":"2024","unstructured":"Chen Y, Deng Y, Li Y, et al. Oxygen-independent radiodynamic therapy: radiation-boosted chemodynamics for reprogramming the tumor immune environment and enhancing antitumor immune response. ACS Appl Mater Interfaces. 2024;16(17):21546\u201356. https:\/\/doi.org\/10.1021\/acsami.4c00793.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"6","key":"3061_CR12","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S1470-2045(24)00037-8","volume":"25","author":"AM Scott","year":"2024","unstructured":"Scott AM, Zeglis BM, Lapi SE, et al. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. Lancet Oncol. 2024;25(6):e250\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(24)00037-8.","journal-title":"Lancet Oncol"},{"key":"3061_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41392-024-02041-6","volume":"23","author":"M Radi","year":"2024","unstructured":"Radi M, Argyrou M, Gosewisch A, et al. Radiopharmaceuticals and their applications in medicine. Nat Rev Drug Discov. 2024;23:452\u201370. https:\/\/doi.org\/10.1038\/s41392-024-02041-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3061_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.7150\/thno.3645","volume":"2","author":"RP Baum","year":"2012","unstructured":"Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy\u2014the Bad Berka experience. Theranostics. 2012;2(5):437\u201347. https:\/\/doi.org\/10.7150\/thno.3645.","journal-title":"Theranostics"},{"key":"3061_CR15","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.04.004","author":"A Brink","year":"2025","unstructured":"Brink A, Paez D, Estrada Lobato E, et al. New targets for imaging in nuclear medicine. Semin Nucl Med. 2025. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.04.004.","journal-title":"Semin Nucl Med"},{"issue":"5","key":"3061_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.rpor.2011.10.008","volume":"17","author":"E Sanz-Rodr\u00edguez","year":"2012","unstructured":"Sanz-Rodr\u00edguez E, et al. Recommendations of the Spanish societies of radiation oncology and medical physics on the use of radiopharmaceuticals in oncology. Rep Pract Oncol Radiother. 2012;17(5):274\u201382. https:\/\/doi.org\/10.1016\/j.rpor.2011.10.008.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"5","key":"3061_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.2967\/jnumed.115.163865","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Liu E, Blume JD, et al. Safety and efficacy of 68Ga-DOTATATE PET\/CT for diagnosing and staging neuroendocrine tumors. J Nucl Med. 2016;57(5):708\u201314. https:\/\/doi.org\/10.2967\/jnumed.115.163865.","journal-title":"J Nucl Med"},{"issue":"1\u20132","key":"3061_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nima.2004.03.008","volume":"527","author":"P Olivier","year":"2004","unstructured":"Olivier P. Nuclear oncology, a fast growing field of nuclear medicine. Nucl Instrum Methods Phys Res A. 2004;527(1\u20132):4\u20138.","journal-title":"Nucl Instrum Methods Phys Res A"},{"issue":"6","key":"3061_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3061_CR20","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","volume":"18","author":"MR Gill","year":"2017","unstructured":"Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017;18(7):e414\u201323. https:\/\/doi.org\/10.1016\/S1470-2045(17)30379-0.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3061_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jmir.2019.09.005","volume":"66","author":"G Currie","year":"2019","unstructured":"Currie G, Hawk KE, Rohren E, Vial A, Klein R. Machine learning and deep learning in medical imaging: intelligent imaging. J Med Radiat Sci. 2019;66(4):292\u20138. https:\/\/doi.org\/10.1016\/j.jmir.2019.09.005.","journal-title":"J Med Radiat Sci"},{"issue":"22","key":"3061_CR22","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1001\/jama.2016.17438","volume":"316","author":"AK Jha","year":"2016","unstructured":"Jha AK, Topol EJ. Adapting to artificial intelligence: radiologists and pathologists as information specialists. JAMA. 2016;316(22):2353\u20134. https:\/\/doi.org\/10.1001\/jama.2016.17438.","journal-title":"JAMA"},{"issue":"3","key":"3061_CR23","first-page":"1072","volume":"49","author":"K Sandgren","year":"2022","unstructured":"Sandgren K, Velikyan I, Garske-Rom\u00e1n U, et al. Individualized dosimetry of 177Lu-DOTATATE therapy using deep learning\u2013assisted SPECT\/CT segmentation. Eur J Nucl Med Mol Imaging. 2022;49(3):1072\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3061_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2023.100120","volume":"2","author":"R Meshaka","year":"2023","unstructured":"Meshaka R, Biassoni L, Chambers G, Voss S, Orr K. Nuclear medicine techniques in paediatric body oncology: present and future. EJC Paediatr Oncol. 2023;2:100120. https:\/\/doi.org\/10.1016\/j.ejcped.2023.100120.","journal-title":"EJC Paediatr Oncol"},{"issue":"6","key":"3061_CR25","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1148\/rg.2020200021","volume":"40","author":"JFG Marin","year":"2020","unstructured":"Marin JFG, Nunes RF, Coutinho AM, et al. Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. Radiographics. 2020;40(6):1715\u201340. https:\/\/doi.org\/10.1148\/rg.2020200021.","journal-title":"Radiographics"},{"issue":"4","key":"3061_CR26","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.220157","volume":"5","author":"BJ Burkett","year":"2023","unstructured":"Burkett BJ, Bartlett DJ, McGarrah PW, et al. A review of theranostics: perspectives on emerging approaches and clinical advancements. Radiology. 2023;5(4):e220157. https:\/\/doi.org\/10.1148\/rycan.220157.","journal-title":"Radiology"},{"issue":"3","key":"3061_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/1874471011306030004","volume":"6","author":"A Dash","year":"2013","unstructured":"Dash A, Pillai MRA, Knapp FF. Targeted radionuclide therapy\u2014an overview. Curr Radiopharm. 2013;6(3):152\u201380. https:\/\/doi.org\/10.2174\/1874471011306030004.","journal-title":"Curr Radiopharm"},{"issue":"2","key":"3061_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"3061_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104377","volume":"198","author":"L Santos","year":"2024","unstructured":"Santos L, Moreira JN, Abrunhosa A, Gomes C. Brain metastasis: an insight into novel molecular targets for theranostic approaches. Crit Rev Oncol Hematol. 2024;198:104377. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104377.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"3061_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2967\/jnumed.120.257592","volume":"62","author":"H Zhang","year":"2021","unstructured":"Zhang H, Chen J, Liu Y, et al. Development and first-in-human study of a novel PET radiopharmaceutical targeting integrin \u03b1v\u03b23. J Nucl Med. 2021;62(6):807\u201313. https:\/\/doi.org\/10.2967\/jnumed.120.257592.","journal-title":"J Nucl Med"},{"key":"3061_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.nucmedbio.2020.08.004","volume":"92","author":"JL Hatcher Lamarre","year":"2021","unstructured":"Hatcher Lamarre JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC. Alpha emitting nuclides for targeted therapy. Nucl Med Biol. 2021;92:228\u201340. https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.08.004.","journal-title":"Nucl Med Biol"},{"issue":"Suppl 1","key":"3061_CR32","doi-asserted-by":"publisher","first-page":"199S","DOI":"10.2967\/jnumed.105.041293","volume":"46","author":"DA Mulford","year":"2005","unstructured":"Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted \u03b1-particle therapy. J Nucl Med. 2005;46(Suppl 1):199S-204S. https:\/\/doi.org\/10.2967\/jnumed.105.041293.","journal-title":"J Nucl Med"},{"issue":"4","key":"3061_CR33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.34172\/apb.2023.079","volume":"13","author":"R Ritawidya","year":"2023","unstructured":"Ritawidya R, Wongso H, Effendi N, et al. Lutetium-177-labeled prostate-specific membrane antigen-617 for molecular imaging and targeted radioligand therapy of prostate cancer. Adv Pharm Bull. 2023;13(4):701\u201311. https:\/\/doi.org\/10.34172\/apb.2023.079.","journal-title":"Adv Pharm Bull"},{"issue":"8","key":"3061_CR34","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2967\/jnumed.115.156711","volume":"56","author":"AT Soderlund","year":"2015","unstructured":"Soderlund AT, Chaal J, Tjio G, Totman JJ, Conti M, Townsend DW. Beyond 18F-FDG: characterization of PET\/CT and PET\/MR scanners for a comprehensive set of positron emitters of growing application\u201418F, 11C, 89Zr, 124I, 68Ga, and 90Y. J Nucl Med. 2015;56(8):1285\u201391. https:\/\/doi.org\/10.2967\/jnumed.115.156711.","journal-title":"J Nucl Med"},{"issue":"1","key":"3061_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00259-010-1568-y","volume":"38","author":"BF Hutton","year":"2011","unstructured":"Hutton BF, Buvat I, Beekman FJ. Review and current status of SPECT imaging. Eur J Nucl Med Mol Imaging. 2011;38(1):14\u201328. https:\/\/doi.org\/10.1007\/s00259-010-1568-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3061_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41585-022-00698-z","volume":"20","author":"TW Barber","year":"2023","unstructured":"Barber TW, Thomas P, Hsieh J, et al. Prostate-specific membrane antigen targeting in metastatic castration-resistant prostate cancer: opportunities and challenges. Nat Rev Urol. 2023;20(2):99\u2013114. https:\/\/doi.org\/10.1038\/s41585-022-00698-z.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"3061_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4103\/0972-3919","volume":"32","author":"KG Kallur","year":"2017","unstructured":"Kallur KG, Ramachandra PG, Rajkumar K, et al. Clinical utility of Gallium-68 PSMA PET\/CT scan for prostate cancer. Indian J Nucl Med. 2017;32(2):110\u20137. https:\/\/doi.org\/10.4103\/0972-3919.","journal-title":"Indian J Nucl Med"},{"issue":"8","key":"3061_CR38","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170\u20136. https:\/\/doi.org\/10.2967\/jnumed.115.171397.","journal-title":"J Nucl Med"},{"issue":"3","key":"3061_CR39","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","volume":"48","author":"S Ballal","year":"2021","unstructured":"Ballal S, Yadav MP, Kramer V, et al. A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET\/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48(3):942\u20134. https:\/\/doi.org\/10.1007\/s00259-020-04990-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3061_CR40","volume-title":"Mathematics and physics of emerging biomedical imaging","author":"National Research Council (US) and Institute of Medicine (US) Committee on the Mathematics and Physics of Emerging Dynamic Biomedical Imaging","year":"1996","unstructured":"National Research Council (US) and Institute of Medicine (US) Committee on the Mathematics and Physics of Emerging Dynamic Biomedical Imaging. Mathematics and physics of emerging biomedical imaging. Washington (DC): National Academies Press (US); 1996."},{"issue":"2","key":"3061_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.semradonc.2010.11.004","volume":"21","author":"RL Wahl","year":"2011","unstructured":"Wahl RL, Herman JM, Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol. 2011;21(2):88\u2013100. https:\/\/doi.org\/10.1016\/j.semradonc.2010.11.004.","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"3061_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7150\/thno.7471","volume":"4","author":"I Velikyan","year":"2014","unstructured":"Velikyan I. Prospective of 68Ga-radiopharmaceutical development. Theranostics. 2014;4(1):47\u201380. https:\/\/doi.org\/10.7150\/thno.7471.","journal-title":"Theranostics"},{"issue":"7","key":"3061_CR43","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00259-011-1787-2","volume":"38","author":"E Laffon","year":"2011","unstructured":"Laffon E, Lamare F, Longere B, et al. Comparative performance of OSEM and 3D iterative reconstruction algorithms for tumor FDG-PET imaging. Eur J Nucl Med Mol Imaging. 2011;38(7):1221\u20138. https:\/\/doi.org\/10.1007\/s00259-011-1787-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3061_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/796025","volume":"2011","author":"MM Khalil","year":"2011","unstructured":"Khalil MM, Tremoleda JL, Bayomy TB, Gsell W. Molecular SPECT imaging: an overview. Int J Mol Imaging. 2011;2011:796025. https:\/\/doi.org\/10.1155\/2011\/796025.","journal-title":"Int J Mol Imaging"},{"issue":"9","key":"3061_CR45","first-page":"1613","volume":"33","author":"MK O'Connor","year":"1992","unstructured":"O\u2019Connor MK, Kvols LK, Brown ML, et al. Dosimetry and biodistribution of an iodine-123-labeled somatostatin analog in patients with neuroendocrine tumors. J Nucl Med. 1992;33(9):1613\u20139.","journal-title":"J Nucl Med"},{"issue":"9","key":"3061_CR46","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1210\/jc.2012-1043","volume":"97","author":"M Schlumberger","year":"2012","unstructured":"Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. J Clin Endocrinol Metab. 2012;97(9):2683\u201390. https:\/\/doi.org\/10.1210\/jc.2012-1043.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"3061_CR47","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.176701","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941\u20134. https:\/\/doi.org\/10.2967\/jnumed.116.176701.","journal-title":"J Nucl Med"},{"issue":"3","key":"3061_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1213755.","journal-title":"N Engl J Med"},{"issue":"2","key":"3061_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1055\/s-0043-1764306","volume":"22","author":"N Kumar","year":"2023","unstructured":"Kumar N, Gupta P, Shamim SA, et al. 188 Re-N-DEDC Lipiodol for treatment of hepatocellular carcinoma (HCC)-a clinical and prospective study to assess in-vivo distribution in patients and clinical feasibility of therapy. World J Nucl Med. 2023;22(2):114\u201323. https:\/\/doi.org\/10.1055\/s-0043-1764306.","journal-title":"World J Nucl Med"},{"issue":"2","key":"3061_CR50","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/bcp.14942","volume":"87","author":"RP Baum","year":"2021","unstructured":"Baum RP, Prasad V, M\u00fcller D, et al. Molecular theranostics for personalized patient management of neuroendocrine tumors and prostate cancer. Br J Clin Pharmacol. 2021;87(2):438\u201353. https:\/\/doi.org\/10.1111\/bcp.14942.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3061_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031447","volume":"23","author":"O Rogoza","year":"2022","unstructured":"Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of somatostatin signalling in neuroendocrine tumours. Int J Mol Sci. 2022;23(3):1447. https:\/\/doi.org\/10.3390\/ijms23031447.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3061_CR52","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1007\/s00259-021-05357-w","volume":"48","author":"P Kumar","year":"2021","unstructured":"Kumar P, Singh H, Satapathy S, Roy SG, Ramesh R, Dash A. Synthesis and preclinical evaluation of a novel 68Ga-labeled somatostatin analog for PET imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2021;48(11):3467\u201375. https:\/\/doi.org\/10.1007\/s00259-021-05357-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3061_CR53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/B978-0-443-06652-8.50013-2","volume-title":"Diagnostic immunohistochemistry","author":"DJ Dabbs","year":"2006","unstructured":"Dabbs DJ. Immunohistology of metastatic carcinoma of unknown primary. In: Dabbs DJ, editor. Diagnostic immunohistochemistry. 2nd ed. Churchill Livingstone; 2006. p. 180\u2013226.","edition":"2"},{"issue":"2","key":"3061_CR54","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1148\/radiol.2021202771","volume":"299","author":"C Lawhn-Heath","year":"2021","unstructured":"Lawhn-Heath C, Salavati A, Behr SC, et al. Prostate-specific membrane antigen PET in prostate cancer. Radiology. 2021;299(2):248\u201360. https:\/\/doi.org\/10.1148\/radiol.2021202771.","journal-title":"Radiology"},{"key":"3061_CR55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4137\/CMO.S6460","volume":"6","author":"A Jeyakumar","year":"2012","unstructured":"Jeyakumar A, Younis T. Trastuzumab for HER2-positive metastatic breast cancer: clinical and economic considerations. Clin Med Insights Oncol. 2012;6:179\u201387. https:\/\/doi.org\/10.4137\/CMO.S6460.","journal-title":"Clin Med Insights Oncol"},{"key":"3061_CR56","doi-asserted-by":"publisher","unstructured":"Santos L, Hrynchak I, Sereno J, et al. (2025) 177Lu-Trastuzumab radionuclide therapy: an effective approach for resistant brain metastases in HER2+ breast cancer. https:\/\/doi.org\/10.21203\/rs.3.rs-6180100\/v1.","DOI":"10.21203\/rs.3.rs-6180100\/v1"},{"issue":"1","key":"3061_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RLU.0000000000001820","volume":"42","author":"GA Ulaner","year":"2017","unstructured":"Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. 89Zr-Trastuzumab PET\/CT for detection of human epidermal growth factor receptor 2\u2013positive metastases in patients with human epidermal growth factor receptor 2\u2013negative primary breast cancer. Clin Nucl Med. 2017;42(1):1\u20137. https:\/\/doi.org\/10.1097\/RLU.0000000000001820.","journal-title":"Clin Nucl Med"},{"key":"3061_CR58","doi-asserted-by":"publisher","first-page":"153601211774538","DOI":"10.1177\/1536012117745386","volume":"17","author":"AVF Massicano","year":"2018","unstructured":"Massicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in nuclear medicine for imaging and therapy. Mol Imaging. 2018;17:1536012117745386. https:\/\/doi.org\/10.1177\/1536012117745386.","journal-title":"Mol Imaging"},{"issue":"1","key":"3061_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-006-0087-6","volume":"6","author":"RO Dillman","year":"2006","unstructured":"Dillman RO. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin Exp Med. 2006;6(1):1\u201312. https:\/\/doi.org\/10.1007\/s10238-006-0087-6.","journal-title":"Clin Exp Med"},{"issue":"9","key":"3061_CR60","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3348\/kjr.2023.0091","volume":"24","author":"Y Wang","year":"2023","unstructured":"Wang Y, Gao F. Research progress of CXCR4-targeting radioligands for oncologic imaging. Korean J Radiol. 2023;24(9):871\u201389. https:\/\/doi.org\/10.3348\/kjr.2023.0091.","journal-title":"Korean J Radiol"},{"issue":"11","key":"3061_CR61","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1007\/s00259-021-05271-8","volume":"48","author":"P Herhaus","year":"2021","unstructured":"Herhaus P, Habringer S, Philipp-Abbrederis K, et al. Targeting CXCR4 with [177Lu]Pentixather: a first-in-human study. Eur J Nucl Med Mol Imaging. 2021;48(11):3511\u201321. https:\/\/doi.org\/10.1007\/s00259-021-05271-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"3061_CR62","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2967\/jnumed.114.151902","volume":"56","author":"HJ Wester","year":"2015","unstructured":"Wester HJ, Keller U, Schottelius M, et al. First experience with chemokine receptor CXCR4\u2013targeted PET imaging of patients with solid cancers. J Nucl Med. 2015;56(3):398\u2013404. https:\/\/doi.org\/10.2967\/jnumed.114.151902.","journal-title":"J Nucl Med"},{"issue":"2","key":"3061_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00259-015-3189-7","volume":"43","author":"C Lapa","year":"2016","unstructured":"Lapa C, Herrmann K, Schirbel A, et al. CXCR4-directed imaging in patients with advanced multiple myeloma. Eur J Nucl Med Mol Imaging. 2016;43(2):219\u201329. https:\/\/doi.org\/10.1007\/s00259-015-3189-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3061_CR64","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00259-020-04881-0","volume":"48","author":"H H\u00e4nscheid","year":"2021","unstructured":"H\u00e4nscheid H, Lapa C, Buck AK, et al. Dosimetry and first therapy results with [177Lu] Pentixather in patients with advanced hematologic malignancies. Eur J Nucl Med Mol Imaging. 2021;48(1):365\u201376. https:\/\/doi.org\/10.1007\/s00259-020-04881-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3061_CR65","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI pet\/ct: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.227967.","journal-title":"J Nucl Med"},{"issue":"5","key":"3061_CR66","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2967\/jnumed.122.264275","volume":"64","author":"M R\u00f6hrich","year":"2023","unstructured":"R\u00f6hrich M, Naumann P, Giesel FL, et al. Fibroblast activation protein\u2013specific PET\/CT imaging in patients with various cancers using 68Ga-FAPI-46 and 68Ga-FAPI-74: a prospective, randomized, multicenter study. J Nucl Med. 2023;64(5):707\u201313. https:\/\/doi.org\/10.2967\/jnumed.122.264275.","journal-title":"J Nucl Med"},{"issue":"9","key":"3061_CR67","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Giesel F, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322. https:\/\/doi.org\/10.2967\/jnumed.118.210435.","journal-title":"J Nucl Med"},{"issue":"4","key":"3061_CR68","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.119.234146","volume":"61","author":"T Watabe","year":"2020","unstructured":"Watabe T, Liu Y, Kaneda-Nakashima K, et al. Theranostics targeting fibroblast activation protein in a mouse model of pancreatic ductal adenocarcinoma. J Nucl Med. 2020;61(4):563\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.234146.","journal-title":"J Nucl Med"},{"key":"3061_CR69","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266345","author":"J Lau","year":"2023","unstructured":"Lau J, Wang J, Kuo HT, et al. Preclinical development of PNT6555: a potent and selective boronic acid\u2013based fibroblast activation protein inhibitor for radioligand therapy. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/jnumed.123.266345.","journal-title":"J Nucl Med"},{"key":"3061_CR70","unstructured":"Zhou Y, Ma Z, Zhang H, et al. Development of ibuprofen-conjugated FAPI radioligands with enhanced tumor retention for cancer theranostics. Eur J Nucl Med Mol Imaging. 2025; [in press]."},{"issue":"23","key":"3061_CR71","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1215","volume":"29","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu H, Roy EK, et al. Fibroblast activation protein\u2013targeted radioligand therapy in patients with advanced radioiodine-refractory thyroid cancer: a first-in-human phase I study. Clin Cancer Res. 2023;29(23):4740\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1215.","journal-title":"Clin Cancer Res"},{"key":"3061_CR72","unstructured":"Baum RP, Kratochwil C, Bartel T, et al. Clinical experience with therapeutic FAP-targeted radioligand therapy using Lu-177-FAPI-2286 in advanced sarcoma. J Nucl Med. 2023."},{"issue":"1","key":"3061_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7150\/thno.3463","volume":"2","author":"MK Yu","year":"2012","unstructured":"Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2(1):3\u201344. https:\/\/doi.org\/10.7150\/thno.3463.","journal-title":"Theranostics"},{"issue":"1","key":"3061_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5005\/jp-journals-10028-1055","volume":"47","author":"HR Kulkarni","year":"2013","unstructured":"Kulkarni HR, Baum RP. Molecular imaging using PET\/CT applying 68Ga-labeled tracers and targeted radionuclide therapy: theranostics on the way to personalized medicine. J Postgrad Med Educ Res. 2013;47(1):47\u201353.","journal-title":"J Postgrad Med Educ Res"},{"issue":"2","key":"3061_CR75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","volume":"49","author":"A Dash","year":"2015","unstructured":"Dash A, Pillai MR, Knapp FF. Production of 177Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging. 2015;49(2):85\u2013107. https:\/\/doi.org\/10.1007\/s13139-014-0315-z.","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"3061_CR76","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1053\/j.semnuclmed.2025.04.004","volume":"55","author":"A Brink","year":"2025","unstructured":"Brink A, Paez D, Estrada Lobato E, et al. New targets for imaging in nuclear medicine. Semin Nucl Med. 2025;55(4):101\u201315. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.04.004.","journal-title":"Semin Nucl Med"},{"issue":"9\u201310","key":"3061_CR77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1515\/znc-2024-0043","volume":"79","author":"A Shah","year":"2024","unstructured":"Shah A, Dabhade A, Bharadia H, et al. Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects. Zeitschrift f\u00fcr Naturforschung C. 2024;79(9\u201310):235\u201366. https:\/\/doi.org\/10.1515\/znc-2024-0043.","journal-title":"Zeitschrift f\u00fcr Naturforschung C"},{"issue":"3","key":"3061_CR78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.semnuclmed.2008.01.003","volume":"38","author":"DW Townsend","year":"2008","unstructured":"Townsend DW. Positron emission tomography\/computed tomography. Semin Nucl Med. 2008;38(3):152\u201366. https:\/\/doi.org\/10.1053\/j.semnuclmed.2008.01.003.","journal-title":"Semin Nucl Med"},{"issue":"2","key":"3061_CR79","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7150\/thno.13946","volume":"6","author":"J Sorensen","year":"2016","unstructured":"Sorensen J, Velikyan I, Sandberg D, Wennborg A, Sundin A. First-in-human molecular imaging of HER2 expression in breast cancer metastases using [68Ga]ABY-025 PET\/CT. Theranostics. 2016;6(2):262\u201371. https:\/\/doi.org\/10.7150\/thno.13946.","journal-title":"Theranostics"},{"issue":"2","key":"3061_CR80","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"6","key":"3061_CR81","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2967\/jnumed.119.237888","volume":"61","author":"V Prasad","year":"2020","unstructured":"Prasad V, Baum RP, Miederer M, et al. First-in-human study of ^68Ga-FAPI PET\/CT in patients with breast cancer. J Nucl Med. 2020;61(6):861\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.237888.","journal-title":"J Nucl Med"},{"issue":"1","key":"3061_CR82","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2967\/jnumed.120.249468","volume":"62","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann M, Buck AK, Zhu B, et al. Clinical value of ^68Ga-PSMA-11 PET imaging in recurrent prostate cancer: prospective multicenter trial. J Nucl Med. 2021;62(1):15\u201322. https:\/\/doi.org\/10.2967\/jnumed.120.249468.","journal-title":"J Nucl Med"},{"issue":"8","key":"3061_CR83","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/ph14080713","volume":"14","author":"U Hennrich","year":"2021","unstructured":"Hennrich U, Eder M. [68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals (Basel). 2021;14(8):713. https:\/\/doi.org\/10.3390\/ph14080713.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"3061_CR84","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"10","key":"3061_CR85","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2967\/jnumed.120.248721","volume":"61","author":"D Pfister","year":"2020","unstructured":"Pfister D, Schonberger H, Rank CM, et al. Quantitative change in PSMA expression in mCRPC under androgen deprivation monitored with ^68Ga-PSMA-11 PET imaging. J Nucl Med. 2020;61(10):1531\u20135. https:\/\/doi.org\/10.2967\/jnumed.120.248721.","journal-title":"J Nucl Med"},{"issue":"10","key":"3061_CR86","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.192094","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, B\u00f6gemann M, Yordanova A, et al. Radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2017;58(10):1624\u201331. https:\/\/doi.org\/10.2967\/jnumed.117.192094.","journal-title":"J Nucl Med"},{"issue":"1","key":"3061_CR87","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40658-022-00455-9","volume":"9","author":"S Gnesin","year":"2022","unstructured":"Gnesin S, Vontobel P, Munk S, et al. Quantitative dosimetry for radioiodine using ^124I-PET\/MRI in thyroid cancer patients. EJNMMI Phys. 2022;9(1):16. https:\/\/doi.org\/10.1186\/s40658-022-00455-9.","journal-title":"EJNMMI Phys"},{"key":"3061_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jrras.2023.100564","volume":"16","author":"HTP Hung","year":"2023","unstructured":"Hung HTP, Tuyen PN, Tai DT, Duong NT, Giang TTN, Quang NT, et al. Assessment of radiation exposure in a nuclear medicine department of an oncology hospital. J Radiat Res Appl Sci. 2023;16:100564. https:\/\/doi.org\/10.1016\/j.jrras.2023.100564.","journal-title":"J Radiat Res Appl Sci"},{"issue":"1","key":"3061_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the ATA guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid"},{"issue":"6","key":"3061_CR90","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1530\/eje.1.02275","volume":"154","author":"F Pacini","year":"2006","unstructured":"Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787\u2013803. https:\/\/doi.org\/10.1530\/eje.1.02275.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"3061_CR91","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2009-08-234351","volume":"115","author":"SJ Horning","year":"2010","unstructured":"Horning SJ, Juweid ME, Sch\u00f6der H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115(4):775\u20137. https:\/\/doi.org\/10.1182\/blood-2009-08-234351.","journal-title":"Blood"},{"issue":"4","key":"3061_CR92","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood.2020007890","volume":"137","author":"A Smith","year":"2021","unstructured":"Smith A, Brown P, Zhang Y, et al. A randomized controlled trial of ^90Y-ibritumomab tiuxetan versus rituximab maintenance in relapsed follicular lymphoma. Blood. 2021;137(4):501\u201310. https:\/\/doi.org\/10.1182\/blood.2020007890.","journal-title":"Blood"},{"issue":"1","key":"3061_CR93","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13036-023-00352-w","volume":"17","author":"MK Farahani","year":"2023","unstructured":"Farahani MK, Gharibshahian M, Rezvani A, Vaez A. Breast cancer brain metastasis: from etiology to state-of-the-art modeling. J Biol Eng. 2023;17(1):41. https:\/\/doi.org\/10.1186\/s13036-023-00352-w.","journal-title":"J Biol Eng"},{"issue":"2","key":"3061_CR94","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11060-023-04217-4","volume":"161","author":"K Patel","year":"2023","unstructured":"Patel K, Chopra R, Singh R, et al. Neurological outcomes following breast cancer brain metastases: a retrospective analysis of 250 cases. J Neurooncol. 2023;161(2):321\u20139. https:\/\/doi.org\/10.1007\/s11060-023-04217-4.","journal-title":"J Neurooncol"},{"key":"3061_CR95","doi-asserted-by":"publisher","first-page":"1103262","DOI":"10.3389\/fnume.2023.1103262","volume":"3","author":"H Dadgar","year":"2023","unstructured":"Dadgar H, Jokar N, Nemati R, Larvie M, Assadi M. PET tracers in glioblastoma: toward neurotheranostics as an individualized medicine approach. Front Nucl Med. 2023;3:1103262. https:\/\/doi.org\/10.3389\/fnume.2023.1103262.","journal-title":"Front Nucl Med"},{"issue":"5","key":"3061_CR96","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11307-021-01578-1","volume":"23","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Chakraborty S, Liu S, et al. The role of radiolabeled RGD peptides for integrin \u03b1v\u03b23-targeted PET imaging in glioblastoma. Mol Imaging Biol. 2021;23(5):641\u201352. https:\/\/doi.org\/10.1007\/s11307-021-01578-1.","journal-title":"Mol Imaging Biol"},{"key":"3061_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.578286","volume":"10","author":"AJ Poot","year":"2020","unstructured":"Poot AJ, Lam MGEH, van Noesel MM. The current status and future potential of theranostics to diagnose and treat childhood cancer. Front Oncol. 2020;10:578286. https:\/\/doi.org\/10.3389\/fonc.2020.578286.","journal-title":"Front Oncol"},{"issue":"5","key":"3061_CR98","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/MPA.0000000000001546","volume":"49","author":"AG Harris","year":"2020","unstructured":"Harris AG, Vinik AI, O\u2019Dorisio TM, O\u2019Dorisio MS. Radioligand theranostics in the management of neuroendocrine tumors. Pancreas. 2020;49(5):599\u2013603. https:\/\/doi.org\/10.1097\/MPA.0000000000001546.","journal-title":"Pancreas"},{"issue":"6","key":"3061_CR99","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2015.63.1883","volume":"34","author":"G Gebhart","year":"2016","unstructured":"Gebhart G, Lamberts LE, Wimana Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer: a prospective study using ^89Zr-trastuzumab PET-CT. J Clin Oncol. 2016;34(6):572\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.63.1883.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3061_CR100","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-019-05490-2","volume":"179","author":"JJ Mulvey","year":"2020","unstructured":"Mulvey JJ, Villa CH, McDevitt MR, et al. Targeted alpha-particle therapy for HER2-positive breast cancer using trastuzumab labeled with 225Ac: preclinical evaluation. Breast Cancer Res Treat. 2020;179(1):145\u201355. https:\/\/doi.org\/10.1007\/s10549-019-05490-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3061_CR101","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.seminoncol.2010.11.005","volume":"38","author":"K Chen","year":"2011","unstructured":"Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol. 2011;38(1):70\u201386. https:\/\/doi.org\/10.1053\/j.seminoncol.2010.11.005.","journal-title":"Semin Oncol"},{"issue":"2","key":"3061_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020205","volume":"12","author":"R Danieli","year":"2022","unstructured":"Danieli R, Milano A, Gallo S, et al. Personalized dosimetry in targeted radiation therapy: a look to methods, tools and critical aspects. J Pers Med. 2022;12(2):205. https:\/\/doi.org\/10.3390\/jpm12020205.","journal-title":"J Pers Med"},{"issue":"Suppl 3","key":"3061_CR103","doi-asserted-by":"publisher","first-page":"60S","DOI":"10.2967\/jnumed.121.262977","volume":"62","author":"N Pandit-Taskar","year":"2021","unstructured":"Pandit-Taskar N, Iravani A, Lee D, et al. Dosimetry in clinical radiopharmaceutical therapy of cancer: practicality versus perfection in current practice. J Nucl Med. 2021;62(Suppl 3):60S-72S. https:\/\/doi.org\/10.2967\/jnumed.121.262977.","journal-title":"J Nucl Med"},{"issue":"1","key":"3061_CR104","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/S1470-2045(24)00395-4","volume":"26","author":"H Hricak","year":"2025","unstructured":"Hricak H, Mayerhoefer ME, Herrmann K, et al. Advances and challenges in precision imaging. Lancet Oncol. 2025;26(1):e34\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(24)00395-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3061_CR105","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/MED.0000000000000300","volume":"24","author":"T Ito","year":"2017","unstructured":"Ito T, Jensen RT. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):15\u201324. https:\/\/doi.org\/10.1097\/MED.0000000000000300.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"3061_CR106","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"3061_CR107","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2967\/jnumed.121.263159","volume":"62","author":"J Calais","year":"2021","unstructured":"Calais J, Czernin J. PSMA expression assessed by PET imaging is a required biomarker for selecting patients for any PSMA-targeted therapy. J Nucl Med. 2021;62(11):1489\u201391. https:\/\/doi.org\/10.2967\/jnumed.121.263159.","journal-title":"J Nucl Med"},{"issue":"3","key":"3061_CR108","doi-asserted-by":"publisher","DOI":"10.2349\/biij.3.3.e49","volume":"3","author":"R Hicks","year":"2007","unstructured":"Hicks R, Lau E, Binns D. Hybrid imaging is the future of molecular imaging. Biomed Imaging Interv J. 2007;3(3):e49. https:\/\/doi.org\/10.2349\/biij.3.3.e49.","journal-title":"Biomed Imaging Interv J"},{"issue":"9","key":"3061_CR109","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.mri.2012.06.001","volume":"30","author":"TE Yankeelov","year":"2012","unstructured":"Yankeelov TE, Peterson TE, Abramson RG, et al. Simultaneous PET-MRI in oncology: a solution looking for a problem? Magn Reson Imaging. 2012;30(9):1342\u201356. https:\/\/doi.org\/10.1016\/j.mri.2012.06.001.","journal-title":"Magn Reson Imaging"},{"issue":"9","key":"3061_CR110","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s00259-024-06718-6","volume":"51","author":"H Song","year":"2024","unstructured":"Song H, Leonio MI, Ferri V, et al. Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Eur J NuclMed Mol Imaging. 2024;51(9):2784\u201393. https:\/\/doi.org\/10.1007\/s00259-024-06718-6.","journal-title":"Eur J NuclMed Mol Imaging"},{"issue":"6","key":"3061_CR111","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sjogreen Gleisner","year":"2022","unstructured":"Sjogreen Gleisner K, Chouin N, Gabina PM, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809. https:\/\/doi.org\/10.1007\/s00259-022-05727-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3061_CR112","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1102\/1470-7330.2013.0005","volume":"13","author":"FC Gaertner","year":"2013","unstructured":"Gaertner FC, F\u00fcrst S, Schwaiger M. PET\/MR: a paradigm shift. Cancer Imaging. 2013;13(1):36\u201352. https:\/\/doi.org\/10.1102\/1470-7330.2013.0005.","journal-title":"Cancer Imaging"},{"issue":"3","key":"3061_CR113","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3174\/ajnr.A7762","volume":"44","author":"N Soni","year":"2023","unstructured":"Soni N, Ora M, Jena A, et al. Amino acid tracer PET MRI in glioma management: what a neuroradiologist needs to know. AJNR Am J Neuroradiol. 2023;44(3):236\u201346. https:\/\/doi.org\/10.3174\/ajnr.A7762.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"9","key":"3061_CR114","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jacr.2004.05.002","volume":"1","author":"C Foens","year":"2004","unstructured":"Foens C. Emerging technologies in radiation oncology and nuclear medicine: an overview of their use and regulation. J Am Coll Radiol. 2004;1(9):619\u201323. https:\/\/doi.org\/10.1016\/j.jacr.2004.05.002.","journal-title":"J Am Coll Radiol"},{"issue":"6","key":"3061_CR115","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","volume":"25","author":"F Giammarile","year":"2024","unstructured":"Giammarile F, Paez D, Zimmermann R, Cutler CS, Jalilian A, Korde A, et al. Production and regulatory issues for theranostics. Lancet Oncol. 2024;25(6):e260\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(24)00041-X.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3061_CR116","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11886-022-01749-7","volume":"24","author":"P Herscovitch","year":"2022","unstructured":"Herscovitch P. Regulatory agencies and PET\/CT imaging in the clinic. Curr Cardiol Rep. 2022;24(10):1361\u201371. https:\/\/doi.org\/10.1007\/s11886-022-01749-7.","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"3061_CR117","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1148\/radiol.2303021397","volume":"230","author":"MK Kalra","year":"2004","unstructured":"Kalra MK, Maher MM, Toth TL, et al. Strategies for CT radiation dose optimization. Radiology. 2004;230(3):619\u201328. https:\/\/doi.org\/10.1148\/radiol.2303021397.","journal-title":"Radiology"},{"issue":"6","key":"3061_CR118","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrclinonc.2010.67","volume":"7","author":"V Goh","year":"2010","unstructured":"Goh V, Halligan S, Bartram CI. Current status and future directions of colorectal cancer imaging. Nat Rev Clin Oncol. 2010;7(6):331\u201345. https:\/\/doi.org\/10.1038\/nrclinonc.2010.67.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 2","key":"3061_CR119","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/neuonc\/not207","volume":"15","author":"M Smits","year":"2013","unstructured":"Smits M. Imaging of pediatric brain tumors: a practical approach. Neuro Oncol. 2013;15(Suppl 2):14\u201323. https:\/\/doi.org\/10.1093\/neuonc\/not207.","journal-title":"Neuro Oncol"},{"issue":"2","key":"3061_CR120","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1148\/radiol.2019182578","volume":"293","author":"M Essig","year":"2019","unstructured":"Essig M, Anzalone N, Combs SE, et al. MR imaging of neoplastic CNS lesions: review and recommendations for clinical practice. Radiology. 2019;293(2):229\u201342. https:\/\/doi.org\/10.1148\/radiol.2019182578.","journal-title":"Radiology"},{"issue":"10","key":"3061_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (pluvictoTM): the first FDA-approved radiotherapeuticalfor treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15(10):1292. https:\/\/doi.org\/10.3390\/ph15101292.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"3061_CR122","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.diii.2013.12.016","volume":"95","author":"C Vallin","year":"2014","unstructured":"Vallin C, Blouin P, Venel Y, Maurin L, Sirinelli D. The use of computed tomography and nuclear medicine examinations in paediatric oncology: an analysis of practice in a university hospital. Diagn Interv Imaging. 2014;95(4):411\u20139. https:\/\/doi.org\/10.1016\/j.diii.2013.12.016.","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"3061_CR123","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41181-022-00168-x","volume":"7","author":"A Korde","year":"2022","unstructured":"Korde A, Mikolajczak R, Kolenc P, et al. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2022;7(1):18. https:\/\/doi.org\/10.1186\/s41181-022-00168-x.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"3061_CR124","unstructured":"World Health Organization. Expert Committee on Specifications for Pharmaceutical Preparations: Fifty\u2011sixth report (WHO Technical Report Series No.\u202f1044). Geneva: WHO; December 2022. ISBN\u202f978\u201192\u20114\u2011006382\u20112 (electronic), 978\u201192\u20114\u2011006383\u20119 (print)."},{"issue":"7","key":"3061_CR125","doi-asserted-by":"publisher","first-page":"12913","DOI":"10.3390\/molecules200712913","volume":"20","author":"I Velikyan","year":"2015","unstructured":"Velikyan I. 68Ga-based radiopharmaceuticals: production and application relationship. Molecules. 2015;20(7):12913\u201343. https:\/\/doi.org\/10.3390\/molecules200712913.","journal-title":"Molecules"},{"issue":"4","key":"3061_CR126","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","volume":"22","author":"H Hricak","year":"2021","unstructured":"Hricak H, Abdel-Wahab M, Atun R, et al. Medical imaging and nuclear medicine: a lancet oncology commission. Lancet Oncol. 2021;22(4):e136\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(20)30751-8.","journal-title":"Lancet Oncol"},{"key":"3061_CR127","unstructured":"International Atomic Energy Agency (IAEA). Good manufacturing practices for radiopharmaceuticals. Technical Reports Series No. 469. IAEA; 2010."},{"key":"3061_CR128","unstructured":"Healthcare Common Procedure Coding System (HCPCS) https:\/\/www.cms.gov\/medicare\/coding-billing\/healthcare-common-procedure-system"},{"issue":"1","key":"3061_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.imr.2021.100756","volume":"11","author":"Y Chen","year":"2022","unstructured":"Chen Y. Health technology assessment and economic evaluation: is it applicable for the traditional medicine? Integr Med Res. 2022;11(1):100756. https:\/\/doi.org\/10.1016\/j.imr.2021.100756.","journal-title":"Integr Med Res"},{"issue":"2","key":"3061_CR130","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cpet.2020.11.002","volume":"16","author":"TA Hope","year":"2021","unstructured":"Hope TA, Pampaloni MH. PET\/CT and SPECT\/CT in cancer theranostics. PET Clin. 2021;16(2):125\u201335. https:\/\/doi.org\/10.1016\/j.cpet.2020.11.002.","journal-title":"PET Clin"},{"issue":"8","key":"3061_CR131","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.2967\/jnumed.110.075531","volume":"51","author":"A Boss","year":"2010","unstructured":"Boss A, Bisdas S, Kolb A, et al. Hybrid PET\/MRI of intracranial masses: initial experiences and comparison to PET\/CT. J Nucl Med. 2010;51(8):1198\u2013205. https:\/\/doi.org\/10.2967\/jnumed.110.075531.","journal-title":"J Nucl Med"},{"key":"3061_CR132","doi-asserted-by":"publisher","first-page":"153535082412452","DOI":"10.1177\/15353508241245265","volume":"23","author":"SJ Archibald","year":"2024","unstructured":"Archibald SJ, Holland JP, Korde A, Martins AF, Shuhendler AJ, Scott PJH. Combining nuclear medicine with other modalities: future prospect for multimodality imaging. Mol Imaging. 2024;23:15353508241245264. https:\/\/doi.org\/10.1177\/15353508241245265.","journal-title":"Mol Imaging"},{"issue":"1","key":"3061_CR133","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2020529","volume":"18","author":"G Kumraj","year":"2022","unstructured":"Kumraj G, Pathak S, Shah S, et al. Capacity building for vaccine manufacturing across developing countries: the way forward. Hum Vaccin Immunother. 2022;18(1):2020529. https:\/\/doi.org\/10.1080\/21645515.2021.2020529.","journal-title":"Hum Vaccin Immunother"},{"key":"3061_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.zemedi.2025.03.004","author":"L Strigari","year":"2025","unstructured":"Strigari L, Menichelli D, Rizzini EL, et al. Advancing risk management in nuclear medicine diagnostic and therapy through incident-driven risk management tools. Z Med Phys. 2025. https:\/\/doi.org\/10.1016\/j.zemedi.2025.03.004.","journal-title":"Z Med Phys"},{"issue":"10","key":"3061_CR135","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.7150\/thno.41444","volume":"10","author":"P Mi","year":"2020","unstructured":"Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10(10):4557\u201388. https:\/\/doi.org\/10.7150\/thno.41444.","journal-title":"Theranostics"},{"key":"3061_CR136","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c06019","author":"D Wei","year":"2023","unstructured":"Wei D, Wang J, Wu W, Li Q, Wang X, Ma X, et al. Stimuli-responsive polymer-based nanosystems for cancer theranostics. ACS Nano. 2023. https:\/\/doi.org\/10.1021\/acsnano.3c06019.","journal-title":"ACS Nano"},{"issue":"4","key":"3061_CR137","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.7150\/thno.22056","volume":"8","author":"L Zhou","year":"2018","unstructured":"Zhou L, Wang H, Li Y. Stimuli-responsive nanomedicines for overcoming cancer multidrug resistance. Theranostics. 2018;8(4):1059\u201374. https:\/\/doi.org\/10.7150\/thno.22056.","journal-title":"Theranostics"},{"key":"3061_CR138","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jconrel.2023.10.031","volume":"358","author":"L Tang","year":"2024","unstructured":"Tang L, Lee M, Kempen PJ, Yao C, Choi MR. Multifunctional nanomedicine strategies for cancer theranostics. J Control Release. 2024;358:450\u201367. https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.031.","journal-title":"J Control Release"},{"issue":"12","key":"3061_CR139","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","volume":"4","author":"C Parker","year":"2018","unstructured":"Parker C, Lewington V, Shore N, et al. Targeted alpha therapy, an emerging class of cancer agents: a review. JAMA Oncol. 2018;4(12):1765\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4044.","journal-title":"JAMA Oncol"},{"key":"3061_CR140","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.03.002","author":"L Lopes","year":"2025","unstructured":"Lopes L, Matos AP, Figueiredo G. The evolution of artificial intelligence in nuclear medicine. Semin Nucl Med. 2025. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.03.002.","journal-title":"Semin Nucl Med"},{"key":"3061_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/bmm2.12117","volume":"2024","author":"S Das","year":"2024","unstructured":"Das S, Mazumdar H, Khondakar KR, Kaushik A. Machine learning integrated graphene oxide-based diagnostics, drug delivery, analytical approaches to empower cancer diagnosis. BMEMat. 2024;2024:e12117. https:\/\/doi.org\/10.1002\/bmm2.12117.","journal-title":"BMEMat"},{"key":"3061_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/bmm2.70018","volume":"2025","author":"G Zhang","year":"2025","unstructured":"Zhang G, Wei Y, Ho HP. Self-supervised denoising for medical imaging enhancement. BMEMat. 2025;2025:e70018. https:\/\/doi.org\/10.1002\/bmm2.70018.","journal-title":"BMEMat"},{"issue":"1","key":"3061_CR143","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337. https:\/\/doi.org\/10.1038\/nrc.2016.108.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3061_CR144","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351. https:\/\/doi.org\/10.1038\/nbt.3330.","journal-title":"Nat Biotechnol"},{"issue":"47","key":"3061_CR145","doi-asserted-by":"publisher","first-page":"6569","DOI":"10.1039\/C3TB21076A","volume":"1","author":"W Gao","year":"2013","unstructured":"Gao W, Hu CMJ, Fang RH, Zhang L. Liposome-like nanostructures for drug delivery. J Mater Chem B. 2013;1(47):6569\u201385. https:\/\/doi.org\/10.1039\/C3TB21076A.","journal-title":"J Mater Chem B"},{"issue":"7","key":"3061_CR146","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1039\/C8CS00550H","volume":"48","author":"Y Liu","year":"2019","unstructured":"Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2019;48(7):2053\u2013108. https:\/\/doi.org\/10.1039\/C8CS00550H.","journal-title":"Chem Soc Rev"},{"issue":"11","key":"3061_CR147","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.addr.2010.07.009","volume":"62","author":"J Xie","year":"2010","unstructured":"Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62(11):1064\u201379. https:\/\/doi.org\/10.1016\/j.addr.2010.07.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"3061_CR148","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. https:\/\/doi.org\/10.1038\/natrevmats.2016.14.","journal-title":"Nat Rev Mater"},{"key":"3061_CR149","doi-asserted-by":"publisher","first-page":"e70004","DOI":"10.1002\/bmm2.70004","volume":"2025","author":"P Jiang","year":"2025","unstructured":"Jiang P, Dai Y, Hou Y, et al. Artificial intelligence-assisted design, synthesis and analysis of smart biomaterials. BMEMat. 2025;2025:e70004. https:\/\/doi.org\/10.1002\/bmm2.70004.","journal-title":"BMEMat"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03061-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03061-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03061-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:26:20Z","timestamp":1762424780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03061-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":149,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["3061"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03061-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The funding section has been corrected and acknowledgment section has been added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that they have no known competing financial and\/or non-financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent for publication was obtained from all the authors involved in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"We, all the authors, declare that no generative AI or AI-assisted technologies have been utilized during drafting this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI tools"}}],"article-number":"498"}}